Table 3. Tumor response by MET analysis.
| Cytoplasmic IHC | Membrane IHC | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose (mg) | Primary Tumor Type | Best Tumor Response | Best % Change in SLDa | % Change in Sum of SUVmaxb | Sequencing | FISH | % Pos | H-score | MAX SI | % Pos | H-score | MAX SI |
| 25 | Colon | PD | 30.65 | - | M | Neg | 90 | 90 | 1+ | 0 | 0 | 0 |
| Esophageal | SD | 3.39 | −32.00 | ND | ND | 100 | 200 | 3+ | 1 | 1 | 1+ | |
| NSCLC | SD | 5.00 | −4.94 | M | Neg | 10 | 10 | 1+ | 50 | 50 | 1+ | |
| 50 | Esophageal | PD | 20.97 | −21.55 | W | Neg | 80 | 80 | 1+ | 60 | 70 | 2+ |
| Carcinoma of unknown origin | SD | −6.45 | - | W | Neg | 0 | 0 | 0 | 0 | 0 | 0 | |
| 100 | Appendiceal adenocarcinoma | SD | 1.39 | - | W | Neg | 95 | 155 | 2+ | 10 | 10 | 1+ |
| Bladder | SD | 2.63 | −3.70 | F | Neg | 0 | 0 | 0 | 0 | 0 | 0 | |
| Carcinoma of unknown origin | SD | −5.02 | −31.68 | W | Neg | 1 | 1 | 1+ | 0 | 0 | 0 | |
| NSCLC | SD | 14.05 | - | F | ND | 15 | 15 | 1+ | 0 | 0 | 0 | |
| 150 | Esophageal | PD | 2.02 | −16.67 | W | ND | ND | ND | ND | ND | ND | ND |
| Melanoma | PD | 31.43 | −6.57 | W | Neg | 0 | 0 | 0 | 0 | 0 | 0 | |
| 200 | Kidney | PR | −32.51 | −39.68 | ND | ND | 95 | 105 | 2+ | 40 | 70 | 3+ |
| Ovarian | SD | 10.56 | −13.98 | ND | Neg | 60 | 60 | 1+ | 0 | 0 | 0 | |
| Esophageal | SD | 5.13 | −6.67 | ND | Neg | 95 | 145 | 2+ | 60 | 70 | 2+ | |
| Colon | SD | 6.45 | −6.06 | ND | Neg | 99 | 109 | 2+ | 20 | 20 | 1+ | |
| Prostate | PD | 33.33 | − | F | ND | ND | ND | ND | ND | ND | ND | |
| Colon | PD | 8.92 | − | W | Neg | 80 | 85 | 2+ | 10 | 10 | 1+ | |
| Esophageal | PD | 34.37 | 4.38 | F | ND | 25 | 30 | 2+ | 1 | 1 | 1+ | |
| Kidney | SD | −22.22 | −33.75 | ND | Neg | 95 | 137 | 3+ | 63 | 67 | 3+ | |
| Bladder | PD | 32.35 | 34.26 | F | Neg | 10 | 11 | 2+ | 10 | 16 | 3+ | |
| 300 | Prostate | CR | - | - | W | Neg | ND | ND | ND | ND | ND | ND |
| Kidney | PD | 10.32 | 1.49 | M | Neg | ND | ND | ND | ND | ND | ND | |
| NSCLC | SD | - | −22.22 | W | ND | ND | ND | ND | ND | ND | ND | |
| Stomach | SD | 5.94 | −20.19 | W | Neg | ND | ND | ND | ND | ND | ND | |
| Prostate | SD | - | −36.40 | W | Neg | ND | ND | ND | ND | ND | ND | |
| Prostate | SD | - | - | W | Neg | ND | ND | ND | ND | ND | ND | |
| Ovarian | SD | 19.35 | - | W | Neg | ND | ND | ND | ND | ND | ND | |
| 400 | Prostate | PR | −32.50 | −40.54 | F | ND | ND | ND | ND | ND | ND | ND |
| Head and neck squamous cell carcinoma | SD | −20.00 | - | F | ND | ND | ND | ND | ND | ND | ND | |
| Prostate | SD | 5.19 | −41.83 | ND | Neg | ND | ND | ND | ND | ND | ND | |
| Prostate | SD | −14.29 | - | W | Pos | ND | ND | ND | ND | ND | ND | |
| Prostate | PR | −41.18 | - | ND | Neg | ND | ND | ND | ND | ND | ND | |
| Poorly differentiated adenocarcinoma of gallbladder | SD | 5.17 | - | W | Neg | ND | ND | ND | ND | ND | ND | |
Patients with available data for MET biomarker testing and evaluable best tumor response (site reads), percent change in SLD (site reads), or percent change in sum of SUVmax are shown. aFrom baseline. b1 cm spot; week 5 day 29. F, failed; M, mutated; MAX SI, maximum staining intensity; SD, stable disease; SLD, sum of the longest diameter; ND, not determined; Neg, negative; PD, progressive disease; Pos, positive; PR, partial response; W, wild type.